Abstract
Several meta-analyses and some direct comparative studies of atypical antipsychotics indicate that these medications may be more effective than conventional antipsychotic medications at enhancing cognition. However, differences in studies exist: short-term studies of cognitive enhancement may not provide similar results to long-term studies, while comparative studies are superior to meta-analyses. Direct measurement of changes in functional capacity may be a desirable study feature, and the population studied, including the treatment subjects receive, is likely to have a substantial impact on the results. Additionally, cognitive enhancement is not a stand-alone phenomenon. Depression and negative symptoms, for example, also affect an individual with schizophrenia and his or her functioning in the real world as opposed to within clinical studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
